相关实验视频

Updated: Sep 11, 2025

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

揭示小分子瘤亡因子-α (TNF) 抑制剂的潜力:综合性综述

Yaman Chauhan¹, Akshay Kumawat¹, Abhay Singh¹

¹Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India.

Bioorganic & medicinal chemistry

|August 15, 2025

概括

针对瘤坏死因子-α (TNF-α) 的小分子抑制剂为炎症性疾病提供了抗体治疗的替代方案. 这些口服药物正在临床试验中取得进展,有望改善治疗选择.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
药物发现药物发现药物发现

背景情况:

瘤坏死因子-α (TNF-α) 是自身免疫和炎症性疾病 (如类风湿性关节炎和牛皮) 中的关键细胞因子.
目前针对TNF-α的生物疗法,如单克隆抗体,具有局限性,包括管理挑战.

研究的目的:

提供对小分子TNF-α抑制剂的全面审查.
讨论它们的发现,设计,结构-活动关系和生物评估.
概述这些药物的当前临床结果和未来前景.

主要方法:

关于小分子TNF-α抑制剂的科学文献的综述.
针对TNF-α三元体破坏或TNF-αTNFR相互作用阻断的药物设计策略的分析.
对新兴小分子TNF-α抑制剂的临床前和临床数据的评估.

主要成果:

小分子抑制剂提供了诸如口服生物可用性和成本效益高的生产等优势.
几种小分子TNF-α抑制剂已经显示出有前途,并进展到临床试验.
这些抑制剂通过破坏TNF-α结构或阻断受体相互作用来起作用.

结论:

小分子TNF-α抑制剂代表了炎症和自身免疫性疾病的有前途的治疗途径.
进一步的研究和开发是根据当前的临床结果和未来前景进行的.
这些药物可以克服与现有生物疗法相关的局限性.

关键词:

抗炎药物抗炎药物抗炎药物生物活动是生物活动.在子选中选.信号传输通道的信号传输路径.小分子是小分子.这就是TNF-α.

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...